Ohio State Navbar

Directory

Rebecca Klisovic, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 366-3802

Email: klisovic.3@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Academic Advising

2004 - 2005 Jacob The Ohio State University.
2007 - 2008 Stephen The Ohio State University.
2008 - 2012 Alice Mims The Ohio State University. Graduated 2012.
 

Certifications

1991 - present American Board of Internal Medicine/Certified Internal Medicine: American Board of Internal Medicine
1998 - present North Carolina State License: University of North Carolina
2001 - present Ohio State License: The Ohio State University
2004 - present Americal Board of Internal Medicine/Certified Medical Oncology (#196433): American Board of Internal Medicine
 

Clinical Services

09/01/2001 Outpatient Clinic (Hematology)
07/01/2004 HEM II In Patient Service (James Cancer Hospital)
09/01/2004 HEM III (HNP) In patient Service (James Cancer Hospital, Hematology)
05/01/2007 Blood and Marrow Transplantation (BMT) Inpatient Service (James Cancer Hospital)

Conferences

Ali NS, O'Brien JM, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." In CANCER. (July 2007). 96-102.

Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G. "Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." In BLOOD. (November 2012). abstract #4192-.

Hamadani HM, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S,Tse H, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA. "Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." In BLOOD. (November 2012). abstract #1942-.

Klisovic RB, Wang H, Walker A, Walsh K, Vasu S, Garzon R, Devine SM, Wang J, Garr C, Norris A, Byrd JC, Grever MR, Blum W, Chan KK, Marcucci G. "Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results." In BLOOD. (November 2012). abstract #3616-.

Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Uv V, Liu Z, Schwind S, Mims AS, Klisovic,Rebecca R, Walker A, Grever MR, Villalona-Calero M, Byrd JC, Garzon R, Blum W, Chan KK, Marcucci G. "Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)." In BLOOD. (November 2012). abstract #3578-.

Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G. "Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." In BLOOD. (November 2012). abstract #1949-.

Blum W, Klisovic RB, Walker A, Schwind S, Jiang Y, Wang J, Phelps M, Geyer S, Devine SM, Walsh K, Vasu S, Curfman JP, Schaaf L, Garr C, Kefauver C, Byrd JC, Grever MR, Garzon R, Marcucci G. "Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.." In BLOOD. (November 2012). abstract #2619-.

 

Degrees

1993 B.S., Case Western Reserve University

1997 M.D., The Ohio State University

 

Editorial Activities

2007 Blood
2007 American Journal of Hematology
2007 Cancer Research
 

Honors

1989 - 1993 Ohio Leadership Awards.
1990 - 1993 CWRU Student Leadership Awards.
1992 Tau Beta Pi, Honorary Engineering Society.
1993 Katona Award for Excellence in Biomedical Engineering.
1993 Michelson-Morley Undergraduate Research Prize. Michelson-Morley.
1997 OSU College of Medicine Outstanding Senior Award.
1998 The Whitehead Society Outstanding Intern Award.
2002 AACR workshop "Molecular Biology in Clinical Oncology", selected participant.
2002 ASCO Merit Award.
2002 T32 Fellowship Award.
2010 Certificate of Excellence,Outstanding Achievement in Patient Service. The James Cancer Hospital.
 

Journal Articles

Marcucci, Guido; Bruner, Rebecca J.; Binkley, Philip F.; Xiao, Jim; Chan, Kenneth K.; Parthun, Mark; Davis, Melanie; Fischer, Beth; Shank, Roshini; Moran, Mollie; Byrd, John C.; Grever, Michael. "Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Acute Myeloid Leukemia (AML).." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 317-.

Griffin, John H.; Leung, Joey; Bruner, Rebecca J.; Caligiuri, Michael A.; Briesewitz, Roger. "Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.." Proceedings of the National Academy of Sciences of the United States of America. Vol. 100, no. 13. (January 2003.): 7830-7835.

Shea, Thomas, C; Bruner, Rebecca; Wiley, Joseph, M; Serody, Jonathan, S; Sailer, Scott; Gabriel, Don, A; Capel, Eileen; Moore, Dominic, T; Dent, Georgette; Bentley, Stuart; Brecher, Mark E. "An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies.." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Vol. 9, no. 7. (January 2003.): 443-52.

De Angelo, Daniel J.; Stone, Richard M.; Bruner, Rebecca J.; Caligiuri, Michael A.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald; Sawyers, Charles L.; Lambing, Joe L.; Lokker, Nathalie A.; Giese, Neill A.; Sinha, Vikram; Cooper, Michael R.; Druker, Brian J.; Heinrich, Michael C.. "Phase I clinical results with MLN518, a novel FLT3 antagonist: Tolerability, pharmacokinetics, and pharmacodynamics.." Blood. Vol. 102, no. 11. (January 2003.): 65a-66a.

Bruner, Rebecca J ; Farag, Sherif S.. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Vol. 30, no. 4. (January 2003.): 509-519.

Marcucci,G; Stock,W; Dai,G; Liu,S; Klisovic,R; Klisovic,M,I; Sher,D; Huynh,L; FRANKEL,S; Blum,W; Larson,R,A; Grever,M,R; Byrd,J,C; Chan,K,K. "Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeoid leukemia (AML).." BLOOD. Vol. 104, no. 11. (November 2004.): 331A-331A.

Marcucci,G; Stock,W; Dai,G; Klisovic,M,I; Maharry,K; Shen,T; Liu,S; Sher,D,A; Lucas,D; ZWIEBEL,A; Larson,R,A; Caligiuri,M,A; Bloomfield,C,D; Chan,K,K; Grever,M,R; Byrd,J,C. "G3139, a BCL-2 antisense oligo-nucleotide, in AML.." Annals of hematology. Vol. 83, (January 2004.): S93-4.

Whitman, Susan, P; Liu, Shujun; Vukosavljevic, Tamara; Rush, Laura, J; Yu, Li; Liu, Chunhui; Klisovic, Marko, I; Maharry, Kati; Guimond, Martin; Strout, Matthew, P; Becknell, Brian; Dorrance, Adrienne; Klisovic, Rebecca, B; Plass, Christoph; Bloomfield, Clara, D; Marcucci, Guido; Caligiuri, Michael A. "The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.." Blood. Vol. 106, no. 1. (January 2005.): 345-52.

Byrd, John, C; Marcucci, Guido; Parthun, Mark, R; Xiao, Jim, J; Klisovic, Rebecca, B; Moran, Mollie; Lin, Thomas, S; Liu, Shujun; Sklenar, Amy, R; Davis, Melanie, E; Lucas, David, M; Fischer, Beth; Shank, Roshini; Tejaswi, Sooraj, L; Binkley, Philip; Wright, John; Chan, Kenneth, K; Grever, Michael R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.." Blood. Vol. 105, no. 3. (January 2005.): 959-67.

Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novic S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, and Byrd JC. "Phase I Study of Oblimersen Sodium, an Antisense to Bcl-2, in Untreated Older Patients With Acute Myeloid Leukemia: Pharmacokinetics, Pharmacodynamics, and Clinical Activity." J Clin Oncol. Vol. 23, no. 15. (January 2005.): 1-7.

Whitman,S,P; Liu,S,J; Vukosavljevic,T; Rush,L,J; Yu,L; Liu,C,H; Klisovic,M,I; Maharry,K; Guimond,M; Strout,M,P; Becknell,B; Dorrance,A; Klisovic,R,B; Plass,C; Bloomfield,C,D; Marcucci,G; Caligiuri,M,A. "The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy." BLOOD. Vol. 106, no. 1. (July 2005.): 345-352.

Byrd,J,C; Marcucci,G; Parthun,M,R; Xiao,J,J; Klisovic,R,B; Moran,M; Lin,T,S; Liu,S,J; Sklenar,A,R; Davis,M,E; Lucas,D,M; Fischer,B; Shank,R; Tejaswi,S,L; Binkley,P; Wright,J; Chan,K,K; Grever,M,R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia." BLOOD. Vol. 105, no. 3. (February 2005.): 959-967.

Neviani,P; Santhanam,R; Trotta,R; Notari,M; Blaser,B,W; Liu,S,J; Mao,H; Chang,J,S; Galietta,A; Uttam,A; Roy,D,C; Valtieri,M; Bruner-Klisovic,R; Caligiuri,M,A; Bloomfield,C,D; Marcucci,G; Perrotti,D. "The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein." CANCER CELL. Vol. 8, no. 5. (November 2005.): 355-368.

Liu,Shujun; Pang,Jiuxia; Yu,Jianhua; Liu,Zhongfa; Huynh,LeNguyen; Kearney,Jessica; Paschka,Peter; Klisovic,Rebecca,B; Baiocchi,Robert; Blum,William; Perrotti,Danilo; Marcucci,Guido. "Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-positive cells.." BLOOD. Vol. 108, no. 11. (November 2006.): 132B-132B.

DeAngelo,Daniel,J; Amrein,Philip,C; Kovacsovics,Tibor,J; Klisovic,Rebecca,B; Powell,Bayard,L; Cooper,Michael; Webb,Iain,J; Stone,Richard,M. "Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML).." BLOOD. Vol. 108, no. 11. (November 2006.): 51A-51A.

Blum,William; Marcucci,Guido; Devine,Hollie; Klisovic,Rebecca. "Imatinib mesylate-induced complete cytogenetic response in acute myeloid leukemia with t(5;12)(q33;p13).." BLOOD. Vol. 108, no. 11. (November 2006.): 181B-181B.

Blum,William; Klisovic,Rebecca,B; Kefauver,Cheryl; Johnson,Amy; Phelps,Mitch; Dalton,James,T; Lucas,David; Huynh,Le,Nguyen; Liu,Shujun; Grever,Michael,R; Colevas,A,D; Marcucci,Guido; Byrd,John,C. "Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD).." BLOOD. Vol. 108, no. 11. (November 2006.): 224B-224B.

Ali,Naeem,A; O'Brien,James,M; Blum,William; Klisovic,Rebecca,B; Marcucci,Guido; Phillips,Gary; Marsh,Clay,B; Lemeshow,Stanley; Byrd,John,C; Grever,Michael,R. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.." BLOOD. Vol. 108, no. 11. (November 2006.): 476B-476B.

Sun,Jin; Liu,Shujun; Yu,Jianhua; Wei,Min; Mao,Charlene; Ding,Haiming; Kearney,Jessica; Huynh,LeNguyen; Paschka,Peter; Wang,Dachun; Klisovic,Rebecca,B; Perrotti,Danilo; Chen,Ching-Shih; Blum,Williom,George; Marcucci,Guido. "Characterization of HDACI OSU42 as a novel histone deacetylase inhibitor in AML cell lines.." BLOOD. Vol. 108, no. 11. (November 2006.): 563A-563A.

DeAngelo,Daniel,J; Stone,Richard,M; Heaney,Mark,L; Nimer,Stephen,D; Paquette,Ronald,L; Klisovic,Rebecca,B; Caligiuri,Michael,A; Cooper,Michael,R; Lecerf,Jean-Michel; Karol,Michael,D; Sheng,Shihong; Holford,Nick; T Curtin,Peter; Druker,Brian,J; Heinrich,Michael,C. "Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics." BLOOD. Vol. 108, no. 12. (December 2006.): 3674-3681.

Liu, Zhongfa; Liu, Shujun; Xie, Zhiliang; Blum, William; Perrotti, Danilo; Paschka, Peter; Klisovic, Rebecca; Byrd, John; Chan, Kenneth, K; Marcucci, Guido. "Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.." Nucleic acids research. Vol. 35, no. 5. (January 2007.): -.

Liu S, Klisovic RB , Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Liu Z, Neviani P, Blum W, Chan KK, Perrotti D, and Marcucci G. "Targeting AML1/ETO-HDAC repressor complex: a novel mechanism for valproic acid mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells." J Pharmacol Exp Ther. Vol. 321, no. 3. (January 2007.): 953-960.

Ali NA, O’Brien JM, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow S, Grever MR. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." Cancer. Vol. 110, no. 1. (January 2007.): 96-102.

Blum W, Klisovic RB , Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia." J Clin Oncol. Vol. 25, no. 25. (January 2007.): 3884-3891.

Cheng, Hao; Liu, Zhongfa; Blum, William; Byrd, John, C; Klisovic, Rebecca; Grever, Michael, R; Marcucci, Guido; Chan, Kenneth K. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. Vol. 850, no. 1-2. (January 2007.): 206-212.

Klisovic,Rebecca,B; Coutre,Steven; Kovacsovics,Tibor,J; Kantarjiam,Hagop,M; Tricot,Guido,J; Strovel,Jeffrey,W; Genna,Thomas; Bol,David,K; Hamilton,Michael; Mitchell,Beverly,S. "Clinical-biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and provide hypotheses for patient selection criteria for further clinical trials." BLOOD. Vol. 110, no. 11. (November 2007.): 273A-274A.

Blum,William; Klisovic,Rebecca,B; Johnson,Amy; Kefauver,Cheryl; Phelps,Mitch; Lucas,David; Huynh,LeNguyen; Liu,Shujun; Dalton,James,T; Grever,Michael,R; Marcucci,Guido; Byrd,John,C. "Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule." BLOOD. Vol. 110, no. 11. (November 2007.): 272A-272A.

Hamadani,Mehdi; Elder,Patrick; Awan,Farrukh; Krugh,David; Blum,William; Lin,Thomas; Andritsos,Leslie; Bechtel,Thomas; Blum,Kristie; Klisovic,Rebecca; Devine,Steven,M. "High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG." BLOOD. Vol. 110, no. 11. (November 2007.): 351B-351B.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. "A Phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase I, in patients with high-risk myelodysplasia and acute myeloid leukemia." Clinical Cancer Research. no. 14(8): 2444-9. (January 2008.): -.

Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Elder P, Blum K, Penza S, Lin TS, Klisovic RB, Marcucci G, Farag SS, Devine SM. "Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogenic peripheral blood cell transplantation.." Biol Blood Marrow Transplant. Vol. 14, no. 7. (January 2008.): 783-9.

Wei X, Dai G, Liu Z, Cheng H, Xie Z, Klisovic R, Marcucci G, Chan K. "Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleatide reductase.." http://dmd.aspetjournals.org. Vol. 36, no. 11. (January 2008.): 2227-2233.

Klisovic RB , Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan KK, Marcucci G. "Phase I study of GTI-2040, an anti-sense to ribonucleotide reductase, in combination with high dose cytarabine in patients with acute myeloid leukemia." Clin Cancer Res. Vol. 14, no. 12. (January 2008.): 3889-3895.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehman E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caliguiri MA, Chan KK, Wu LC, Marcucci G. "Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methytransferase activity in acute myeloid leukemia.." Blood. Vol. 11, no. 4. (January 2008.): 2364-73.

Klisovic,Rebecca,B; Stock,Wendy; Cataland,Spero; Klisovic,Marko,I; Liu,Shujun; Bium,William; Green,Margaret; Odenike,Olatoyosi; Godley,Lucy; Burgt,Jennifer,Vanden; Van Laar,Emily; Cullen,Michael; MacLeod,A,Robert; Besterman,Jeffrey,M; Reid,Gregory,K; Byrd,John,C; Marcuccil,Guido. "A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia." CLINICAL CANCER RESEARCH. Vol. 14, no. 8. (April 2008.): 2444-2449.

Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM. "Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.." Biology Of Blood And Marrow Transplantation: Journal Of The American Society For Blood And Marrow Transplantation. Vol. 15, no. 11. (November 2009.): 1422-.

Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R , Blum W, Grever MR, Marcucci G, Chan KK. "A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels." Pharm Res. Vol. 26, no. 6. (March 2009.): 1504-1515.

Blum W, Klisovic RB , Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias." J Clin Onc. Vol. 28, no. 33. (November 2010.): 4919-4925.

Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC.. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias." J Clin Oncol. Vol. 28, no. 33. (November 2010.): 4919-25.

Blum,William; Garzon,Ramiro; Klisovic,Rebecca,B; Schwind,Sebastian; Walker,Alison; Geyer,Susan; Liu,Shujun; Havelange,Violaine; Becker,Heiko; Schaaf,Larry; Mickle,Jon; Devine,Hollie; Kefauver,Cheryl; Devine,Steven,M; Chan,Kenneth,K; Heerema,Nyla,A; Bloomfield,Clara,D; Grever,Michael,R; Byrd,John,C; Villalona-Calero,Miguel; Croce,Carlo,M; Marcucci,Guido. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 107, no. 16. (April 2010.): 7473-7478.

W. Blum, MA Phelps, RB Klisovic, DM Rozewski, W Ni, KA Albanese, B Rovin, C Kefauver, SM Devine, DM Lucas, A Johnson, LJ Schaaf, JC Byrd, G Marcucci, MR Grever. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.." Haematologica. Vol. 95, no. 7. (May 2010.): 1098-1105.

Chen P, Aimiuwu J, Xie Z, Wei X, Liu S, Klisovic R , Marcucci G, Chan KK. "Biochemical modulation of Aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 leukemia cells." AAPS. Vol. 13, no. 1. (March 2011.): 131-140.

KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic , CD Bloomfield, W Blum, and G Marcucci. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." Leukemia. Vol. 26, no. 5. (January 2011.): 1106-1107.

Blum W, Schwind S, Tarighat S, Geyer S, Eisfeld A, Whitman S, Walker A, Klisovic RB, Byrd J, Santhanam R, Wang H, Curfman J, Devine S, Jacob S, Garr C, Kefauver C, Perrotti D, Chan K, Bloomfield C, Caligiuri M, Grever M, Garzon R, Marcucci G. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.

Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, Klisovic R, Mims A, Blum W, Marcucci G, Chan KK. "RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.." Blood. Vol. 119, no. 22. (May 2012.): 5229-5238.

Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R.. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.

Yan P, Frankhouser D, Murphy M, Tam H, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu Yue-Zhong, Whitman S., Metzeler K, Walker A, Klisovic RB, Jacob S,. Grever MR, Byrd J, Bloomfield CD., Garzon R, Blum W, Caligiuri MA., Bundschuh R, Marcucci G. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia." BLOOD. Vol. 120, no. 12. (September 2012.): 2466-2474.

Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic RB, Walker A, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G. "Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia." CLINICAL CANCER RESEARCH. Vol. 19, no. 9. (May 2013.): 2355-2367.

Mendler JH, Maharry K, Becker H, Eisfeld, AK, Senter L, Mrózek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G, Bloomfield CD. "In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.." Haematologica. Vol. 98, no. 8. (August 2013.): e92-4.

Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W.. "Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia." LEUKEMIA & LYMPHOMA. Vol. 54, no. 9. (September 2013.): 1996-2002.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. "PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.." JOURNAL OF CLINICAL INVESTIGATION. Vol. 123, no. 10. (October 2013.): 4144-4157.

Mims A, Walker, AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen C-S, Lee LJ, Jacob S, Mrozek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. "Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia." Leukemia. Vol. 27, no. 4. (April 2013.): 871-878.

Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G.. "In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia." AAPS JOURNAL. Vol. 15, no. 1. (January 2013.): 242-249.

Walker,Alison,R; Klisovic,Rebecca,B; Garzon,Ramiro; Schaaf,Larry,J; Humphries,Kristina; Devine,Steven,M; Byrd,John,C; Grever,Michael,R; Marcucci,Guido; Blum,William. "Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.." Leukemia & lymphoma. Vol. 55, no. 6. (June 2014.): 1304-1308.

Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci G.. "Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.." Leukemia & lymphoma. -.

 

Reference Works

January 1992 Panigutti MA, Merritt K, Bruner RJ, Kraay MJ, Brown SA."Correlation of allergy metal levels, implant alloy, and implant damage in patients undergoing revision joint anthroplasty." .
January 1992 Bruner RJ, Merritt K, Brown SA, Panigutti MA."Incidence of allergy in patients undergoing total joint revision." .
January 1993 Bruner RJ, Merritt K, Brown SA, Kraay MJ."Metal sensitivity in patients undergoing total joint revision." .
January 1995 Shoemaker LH, Bruner RJ, Fristad M, Cromer B."Primary health care problems in adolescents with psychiatric disorders." .
January 2000 Gabriel DA, Shea T, Wiley J, Serody J, Kirby S, Bruner RJ, Capel E, Bigelow S, Morris D, Banderencko N, Brecher M."Use of amifostine to reduce mucositis following total brain irradiation-based autotransplants for lymphoma." .
January 2002 Whitman SP, Guimond M, Blaser B, Klisovic M, Vukosavlijevic T, Bruner RJ, Ruppert AS, Becknell B, Barbosa X, Griffen J, Briesewitz R, Caliguiri."Primary acute myeloid leukemia cells with the FLT3 internal tandem duplication (ITD) and absence of wild-type (WT) FLT3 (FLT3 Genotype) are distinct from AML with either FLT3 or FLT3 genotypes." .
January 2002 De Angelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette R, Klisovic RB, Caligiuri MA, Cooper MR, LeCerf J-M, Lyer G, Heinrich MC, Druker BJ."Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with Acute Myeloid Leukemia (AML)" .
January 2002 Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank R, Moran M, Grever M, Byrd JC."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in fludarabine refactory chronic lymphocytic leukemia." .
January 2002 Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank R, Maran M, Grever M, Byrd JC."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in Fludarabine Refactory Chronic Lymphocytic Leukemia" .
January 2002 Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever M, Byrd JC."A phase I study to determine minimally effective pharmacologic dose (MEPD) of depsipeptide (FR901228) in selected hematologic malignancies." .
January 2002 Sooraj LN, Marcucci G, Byrd JC, Bruner RJ, Fischer B, Hatton P, Grever M, Binkley PF."Cardiovascular response to depsipeptide: Absense of cardiotoxicity in human recipients." .
January 2002 Marcucci G, Bruner RJ, Binkley PF, Xia J, Chan KK, Parthun M, Davis M, Fischer B, Shank R, Mroan M, Byrd JC, Grever M."Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in acute myeloid leukemia." .
January 2003 Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert AJ, Strout MP, Becknell B, Dorrance AM, Bruner RJ, Plass C, Bloomfield CD, Marcucci G, Caliguiri M."Activation of the silenced MLL (ALL-1) wild-type allele in Acute Myeloid Leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death." .
January 2003 De Angelo DJ, Stone RM, Bruner RJ, Caliguiri MA, Heaney ML, Nimer SD, Paquette R, Sawyers CL, Lambing JL, Lokker NA, Giese NA, Sinha V, Cooper MR, Druker BJ, Heinrich MC."Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics." .
January 2004 Marcucci G, Stock W, Dai G, Liu S, Klisovic RB, Klisovic MI, Sher D, Huynh L, Frankel S, Blum W, Larson RA, Grever M, Byrd JC, Chan KK."Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in Acute Myeloid Leukemia (AML)" .
January 2005 Neviani P, Santhanam R, Trotta R, Notari M, Blaser B, Chang J, Liu S, Mao K, Oaks J, Roy D, Valtieri M, Klisovic RB, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D."Resetting PP2A tumor suppressor activity overcomes BCR/ABL leukemogenic potential in blast crisis CML" .
January 2005 Klisovic RB, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M, Marcucci G."A phase I study of GTI-2040, and antisense to Ribonucleotide Reductase (RNR) in combination with High-Dose Cytarabine (HiDAC) in relapsed or refactory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and clinical results." .
January 2005 Blum W, Klisovic RB, Liu S, Byrd JC, Liu Z, Chan KK, Kefauver C, Huynh L, Grever MR, Marcucci G."Phase I study of low dose decitabine in patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and clinical activity." .
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD, Grever M, Marcucci G, Byrd JC."Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, phamacokinetics, and pharmacodynamics." .
November 2006 Sun J, Liu S, Yu J, Wei M, Moa C, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic Rb, Perrotti D, Chen C, Blum W, Marcucci G."Characterization of HDACI OSU42 as a Novel Histone Deacetylas Inhibitor in AML cell lines." .
January 2006 Marcucci G, Klisovic RB, Wei E, Liu S, Liu Z, Chan K, Plass C, Grever MR, Chan K, Blum W."A phase I study of GTI-2040 (6), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML)" .
November 2006 DeAngelo D, Amrein P, Kovacsovics T, Klisovic RB, Powell B, Cooper M, Webb I, Stone R.."Phase 1/2 study of Tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML)." .
November 2006 Blum W, Marcucci G, Devine H, Klisovic RB.."Imatinib Mesylate-Induced complete cytogenetic response in AML Myeloid Leukemia with t(5;12)(q33;p13)" .
November 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton J, Lucas D, Huynh L, Liu S, Grever M, Colevas A, Marcucci G, Byrd J.."Updated results of a phase I study of Flavopiridol in acute leukemias using a novel, pharmacokinetically derived scheduled clinical activity including hyperacute Tumor Lysis Syndrome (TLS) Pharmacokinetics (PK), and Phamacodynamics (PD)" .
November 2006 Ali N, O'Brien J, Blum W, Klisovic RB, Marcucci G, Phillips G, Marsh C, Lemeshow S, Byrd J, Grever M."Hyperglycemia in patients with acute myeloid leukemia is associated with increrased hospital mortality" .
January 2006 Klisovic RB, Blum W, Hackanson B, Kefauver C, Liu s, Liu Z, Chan K, Plass C, Grever M, Byrd JC, Marcucci G."Updated results of a phase I study of low dose decitabine and valporic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation and clinical response." .
November 2006 Liu S, Pang J, Yu J, Liu Z, Huynh L, Paschka P, Klisovic RB, Baiocchi R, Blum W, Perrotti D, Marcucci G."Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and KF-kB in AML1/ETO-postive cells" .
November 2007 Blum W, Klisovic RB, Johnson A, Kefauver C, Phelps M, Lucas D, Huynh L, Liu S, Dalton J, Grever M, Marcucci G, Byrd J."Final results of a dose escalation study of Flavopiridol in acute leukemias using a novel treatment schedule." .
November 2007 Klisovic RB, Coutre S, Kovacsovics T, Kantarjiam H, Tricot G, Strovel J, Genna T, Krugh D, Hamilton M, Mithcell B."Clinical - Biomarker correlations in adult AML patients in a phase I trial of AVN944 support observations of clinical effect and proven hypotheses for patient selection criteria for further clinical trials" .
November 2007 Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K, Klisovic RB, Devine S.."High rates of early donor chimerism and low risk of chronic GV van be achieved in poor risk patients undergoing unrelated do stem cell transplantation using reduced intensity conditioning regimen incorporating Fludarabine, Busulfan, and Rabbit ATG" .
January 2007 Klisovic RB, Tricot G, Coutre S, Kovacsovics T, Genna T, Bol D, Strovel J, Hamilton M, Mitchell B."A phase I trial of AVN944 in patients with advanced hematologic malignancies." .
May 2008 Blum W, Andritsos L, Johnson A, Klisovic RB, Kefauver C, Devine S, Marcucci G, Byrd J."Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL); evidence of activity in acute myeloid leukemia (AML) toxicity in CLL starting dose." .
November 2008 Blum W, Klisovic RB, Liu S, Garzon R, Kefauver C, Liu Z, Mickle J, Devine H, Devine S, Grever M, Chan K, Villalona-Calero M, Byrd J, Marcucci G.."Preliminary results of a Phase II study of low dose decitabine as a single agent in older patients (age>60) with previously untreated acute myeloid leukemia (AML)." Washington D.C.
November 2008 Odenike O, Godwin J, Van Besien K, Huo D, Sher d, Burke P, Smith S, Green M, Melnick J, Wade J, Lester E, Klisovic RB, Baer M, Larson R, Stock W.."Phase II trial of low-dose, subcutaneous decitabine in Myelofibrosis." Washington D.C.
January 2009 Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf LJ, Humphries K, Grever MR, Devine SM, Byrd JC, Marcucci G."Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia" New Orleans.
January 2009 Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic RB, Garzon R, Grever MR, Villalona-Calero M, Byrd JC, Chan KK, Marcuccu G."Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine" New Orleans.
January 2009 Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang Xiaoxia, Schaff L, Schwind S, Becker H, Lui S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W."Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myleoid Leukemia" New Orleans.
May 2009 Blum WG, Klisovic R, Liu S, Kefauver C, Grever MR, Schaaf L, Chan K, Byrd JC, Villalona-Calero M, Marcucci G."Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older" .
April 2009 Aimiuwu J, Chen P, Xie Z, Liu Z, Sarathi V, Liu S, Klisovic RB, Marcucci G, Chan K.."In vitro-in vivo pharmacodynamic analisis of GTI-2040 combined with Arc-C acute myeloid leukemia." .
December 2010 D. Rondelli, M.W. Boyer, L. M. Isola, T. Shore, A. Bacigalupo, R.B. Klisovic, R. Marchiloli, J.D. Goldberg, R. Hoffman, L.R. Silverman,."First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in United States: interim analysis of MPD-RC 101 protocol" Chicago.
November 2010 William Blum, Rebecca B. Klisovic , Ramiro Garzon, Alison Walker, Sebastian Schwind, Shujun Liu, Larry Schaaf, Celia Garr, Steven M. Devine, Michael R. Grever, John C. Byrd, and Guido Marcucci."Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)" Orlando.
January 2011 Alison R. Walker, Klaus H. Metzeler, Susan Geyer, Heiko Becker, Sebastian Schwind, Susan P. Whitman, John Curfman, Yue-Zhong Wu, Danilo Perrotti, Rebecca B. Klisovic , Ramiro Garzon, William Blum, and Guido Marcucci."Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)" .
January 2011 Damiano Rondelli, Judith D. Goldberg, Roberto Marchioli, Luis Isola, Tsiporah B. Shore, Josef T. Prchal, Andrea Bacigalupo, Alessandro Rambaldi, Rebecca B. Klisovic , Vikas Gupta, Bjorn Andreasson, Erin P. Demakos, Leah S. Price, Marco Scarano, Meir Wetzler, Alessandro M. Vannucchi, Vesna Najfeld, Giovanni Barosi, Lewis R. Silverman, and Ronald Hoffman."Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis" .
January 2011 KH Metzeler, A Walker, S Geyer, R Garzon, RB Klisovic,CD Bloomfield, W Blum and G Marcucci."DNMT3A mutations and response to the hypomethylating agentdecitabine in acute myeloid leukemia" .
March 2012 Alice S. Mims, Alison R. Walker, Hongyan Wang, Xiaomeng Huang, Ramasamy Santhanam, Pia Hoellerbauer, Somayeh Tarighat, Kenneth K. Chan, Rebecca B. Klisovic, Danilo Perrotti, Michael A. Caligiuri, John C. Byrd, Ching-Shih Chen, William Blum, Ramiro Garzon, Sebastian Schwind, and Guido Marcucci.."AR-42, a Histone Deacetylase Inhibitor, increases microRNA-29b and sensitizes cells to decitabine treatment: a novel epigenetic-targeting approach in Acute Myeloid Leukemia." Philadelphia.
February 2012 J. Cooper, D. Krugh, J. Duda, J. Roddy, R. Klisovic, M. Lamprecht, J. Beavers-Kirby, C. Hofmeister, J. Dishon-Ritzert, S. Devine."Improving Vaccination of Patients Pre and Post Bone Marrow Transplant." San Diego.
February 2012 Damiano Rondelli, Judith D. Goldberg, Roberto Marchioli, Luis Isola, Tsiporah B. Shore, Josef T. Prchal, Andrea Bacigalupo, Alessandro Rambaldi, Rebecca B. Klisovic , Vikas Gupta, Bjorn Andreasson, Erin P. Demakos, Leah S. Price, Marco Scarano, Meir Wetzler, Alessandro M. Vannucchi, Vesna Najfeld, Giovanni Barosi, Lewis R. Silverman, and Ronald Hoffman."Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis" San Diego.
March 2012 Schwind S, Samadzadeh S, Geyer S, Klisovic RB, Eisfeld A, Walker A, Whitman S,Ramasamy S, Wu Y, Samson J, caligiuri M, Grever M, Perrotti D, Byrd J, Garzon R, Boomfield C."The Combination of Bortezomib (BOR) and Decitabine (DEC): a Phase I Trial in Patients (Pts) with Acute Myeloid Leukemia (AML) targeting FLT3 expression" Chicago.

Presentations

"Idiopathic Hypereosinophilic Syndrome: Potential new treatment and clues to Pathogenesis." Presented at OSU Medical Center Grand Rounds, . (October 2002)

"A Phase I Study of GT12040 in combination with high-dose Cytarabine in refactory or relapsed AML." Presented at NCI CTEP, . (September 2005)

"Clinical Update on CML." Presented at Chillicothe VA Lecture Series, . (August 2005)

"CML." Presented at Upper Valley Medical Center Grand Rounds, . (October 2009)

"Chronic Myeloid Leukemia and Myeloproliferative Disorders." Presented at OSU ASH Review, . (January 2009)

"Chronic Myeloid Leukemia." Presented at OSU American Society of Cancer Review, Columbus, OH. (January 2011)

"Hematology Highlights." Presented at ASCO Review, Columbus, OH. (June 2012)

"Updates in AML." Presented at Leukemia and Lymphoma Society/Genesis Healthcare, . (October 2012)

"Acute Leukemia." Presented at The Ohio State University ASH Review, . (January 2013)

"Chronic Myeloid Leukemia (CML)." Presented at The Nexus, . (April 2013)

"Hematolgy Updates." Presented at American Society of Clinical Oncology (ASCO) Review, . (June 2013)

"Myelofibrosis (MF)." Presented at CME Program, KnowledgeOncology, . (July 2013)